Cargando…
A Case of Gemcitabine-Induced Thrombotic Microangiopathy Treated With Ravulizumab in a Patient With Stage IV Pancreatic Cancer
A 47-year-old male with stage IV pancreatic cancer developed gemcitabine-induced thrombotic microangiopathy (GiTMA) after treatment with gemcitabine and nab-paclitaxel. GiTMA is a rare and life-threatening complication with an incidence ranging from 0.015% to 1.4% and reported mortality rate ranging...
Autores principales: | MacDougall, Kira N, Schwartz, Benjamin, Harewood, Janine, Bukhari, Zaheer, Neculiseanu, Elvira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7931775/ https://www.ncbi.nlm.nih.gov/pubmed/33680585 http://dx.doi.org/10.7759/cureus.13031 |
Ejemplares similares
-
Improvement of Breast Cancer-Associated Pulmonary Tumor Thrombotic Microangiopathy With Carboplatin and Gemcitabine
por: Tran, Helen, et al.
Publicado: (2023) -
Gemcitabine-Induced Renal Thrombotic Microangiopathy
por: Chaudhary, Ankur, et al.
Publicado: (2023) -
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
por: Grall, Maximilien, et al.
Publicado: (2021) -
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
por: Krishnappa, Vinod, et al.
Publicado: (2018) -
Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine
por: Hasan, Askari, et al.
Publicado: (2018)